Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program

Kieren J. Mather, Tohru Funahashi, Yuji Matsuzawa, Sharon Edelstein, George A. Bray, Steven E. Kahn, Jill P. Crandall, Santica Marcovina, Barry Goldstein, Ronald Goldberg

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

OBJECTIVE-To determine whether baseline adiponectin levels or intervention-associated change in adiponectin levels were independently associated with progression to diabetes in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS-Cox proportional hazards analysis was used to evaluate the contribution of adiponectin and treatment-related change in adiponectin to risk of progression to diabetes. RESULTS-Baseline adiponectin was a strong independent predictor of incident diabetes in all treatment groups (hazard ratio per ∼3 μg/ml higher level; 0.61 in the lifestyle, 0.76 in the metformin, and the 0.79 in placebo groups; all P < 0.001, P = 0.13 comparing groups). Baseline differences in adiponectin between sexes and race/ethnicity groups were not reflected in differences in diabetes risk. DPP interventions increased adiponectin levels ([means ± SE] 0.83 ± 0.05 μg/ml in the lifestyle group, 0.23 ± 0.05 μg/ml in the metformin group, and 0.10 ± 0.05 μg/ml in the placebo group; P < 0.001 for increases versus baseline, P < 0.01 comparing groups). These increases were associated with reductions in diabetes incidence independent of baseline adiponectin levels in the lifestyle and placebo groups but not in the met-formin subjects (hazard ratio 0.72 in the lifestyle group (P < 0.001), 0.92 in the metformin group (P = 0.18), and 0.89 in the placebo group; P = 0.02 per ∼1 μg/ml increase, P = 0.02 comparing groups). In the lifestyle group, adjusting for change in weight reduced, but did not remove, the effect of increased adiponectin. CONCLUSIONS-Adiponectin is a powerful marker of diabetes risk in subjects at high risk for diabetes, even after adjustment for weight. An increase in adiponectin in the lifestyle and placebo groups was associated with a reduction in diabetes risk. However, these changes in adiponectin were comparatively small and less strongly related to diabetes outcome than baseline adiponectin levels.

Original languageEnglish (US)
Pages (from-to)980-986
Number of pages7
JournalDiabetes
Volume57
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Adiponectin
Life Style
Placebos
Metformin
Weights and Measures
Research Design

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Mather, K. J., Funahashi, T., Matsuzawa, Y., Edelstein, S., Bray, G. A., Kahn, S. E., ... Goldberg, R. (2008). Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program. Diabetes, 57(4), 980-986. https://doi.org/10.2337/db07-1419

Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program. / Mather, Kieren J.; Funahashi, Tohru; Matsuzawa, Yuji; Edelstein, Sharon; Bray, George A.; Kahn, Steven E.; Crandall, Jill P.; Marcovina, Santica; Goldstein, Barry; Goldberg, Ronald.

In: Diabetes, Vol. 57, No. 4, 04.2008, p. 980-986.

Research output: Contribution to journalArticle

Mather, KJ, Funahashi, T, Matsuzawa, Y, Edelstein, S, Bray, GA, Kahn, SE, Crandall, JP, Marcovina, S, Goldstein, B & Goldberg, R 2008, 'Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program', Diabetes, vol. 57, no. 4, pp. 980-986. https://doi.org/10.2337/db07-1419
Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE et al. Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program. Diabetes. 2008 Apr;57(4):980-986. https://doi.org/10.2337/db07-1419
Mather, Kieren J. ; Funahashi, Tohru ; Matsuzawa, Yuji ; Edelstein, Sharon ; Bray, George A. ; Kahn, Steven E. ; Crandall, Jill P. ; Marcovina, Santica ; Goldstein, Barry ; Goldberg, Ronald. / Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program. In: Diabetes. 2008 ; Vol. 57, No. 4. pp. 980-986.
@article{0305446142924d2482fea6f0f03236b3,
title = "Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program",
abstract = "OBJECTIVE-To determine whether baseline adiponectin levels or intervention-associated change in adiponectin levels were independently associated with progression to diabetes in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS-Cox proportional hazards analysis was used to evaluate the contribution of adiponectin and treatment-related change in adiponectin to risk of progression to diabetes. RESULTS-Baseline adiponectin was a strong independent predictor of incident diabetes in all treatment groups (hazard ratio per ∼3 μg/ml higher level; 0.61 in the lifestyle, 0.76 in the metformin, and the 0.79 in placebo groups; all P < 0.001, P = 0.13 comparing groups). Baseline differences in adiponectin between sexes and race/ethnicity groups were not reflected in differences in diabetes risk. DPP interventions increased adiponectin levels ([means ± SE] 0.83 ± 0.05 μg/ml in the lifestyle group, 0.23 ± 0.05 μg/ml in the metformin group, and 0.10 ± 0.05 μg/ml in the placebo group; P < 0.001 for increases versus baseline, P < 0.01 comparing groups). These increases were associated with reductions in diabetes incidence independent of baseline adiponectin levels in the lifestyle and placebo groups but not in the met-formin subjects (hazard ratio 0.72 in the lifestyle group (P < 0.001), 0.92 in the metformin group (P = 0.18), and 0.89 in the placebo group; P = 0.02 per ∼1 μg/ml increase, P = 0.02 comparing groups). In the lifestyle group, adjusting for change in weight reduced, but did not remove, the effect of increased adiponectin. CONCLUSIONS-Adiponectin is a powerful marker of diabetes risk in subjects at high risk for diabetes, even after adjustment for weight. An increase in adiponectin in the lifestyle and placebo groups was associated with a reduction in diabetes risk. However, these changes in adiponectin were comparatively small and less strongly related to diabetes outcome than baseline adiponectin levels.",
author = "Mather, {Kieren J.} and Tohru Funahashi and Yuji Matsuzawa and Sharon Edelstein and Bray, {George A.} and Kahn, {Steven E.} and Crandall, {Jill P.} and Santica Marcovina and Barry Goldstein and Ronald Goldberg",
year = "2008",
month = "4",
doi = "10.2337/db07-1419",
language = "English (US)",
volume = "57",
pages = "980--986",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program

AU - Mather, Kieren J.

AU - Funahashi, Tohru

AU - Matsuzawa, Yuji

AU - Edelstein, Sharon

AU - Bray, George A.

AU - Kahn, Steven E.

AU - Crandall, Jill P.

AU - Marcovina, Santica

AU - Goldstein, Barry

AU - Goldberg, Ronald

PY - 2008/4

Y1 - 2008/4

N2 - OBJECTIVE-To determine whether baseline adiponectin levels or intervention-associated change in adiponectin levels were independently associated with progression to diabetes in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS-Cox proportional hazards analysis was used to evaluate the contribution of adiponectin and treatment-related change in adiponectin to risk of progression to diabetes. RESULTS-Baseline adiponectin was a strong independent predictor of incident diabetes in all treatment groups (hazard ratio per ∼3 μg/ml higher level; 0.61 in the lifestyle, 0.76 in the metformin, and the 0.79 in placebo groups; all P < 0.001, P = 0.13 comparing groups). Baseline differences in adiponectin between sexes and race/ethnicity groups were not reflected in differences in diabetes risk. DPP interventions increased adiponectin levels ([means ± SE] 0.83 ± 0.05 μg/ml in the lifestyle group, 0.23 ± 0.05 μg/ml in the metformin group, and 0.10 ± 0.05 μg/ml in the placebo group; P < 0.001 for increases versus baseline, P < 0.01 comparing groups). These increases were associated with reductions in diabetes incidence independent of baseline adiponectin levels in the lifestyle and placebo groups but not in the met-formin subjects (hazard ratio 0.72 in the lifestyle group (P < 0.001), 0.92 in the metformin group (P = 0.18), and 0.89 in the placebo group; P = 0.02 per ∼1 μg/ml increase, P = 0.02 comparing groups). In the lifestyle group, adjusting for change in weight reduced, but did not remove, the effect of increased adiponectin. CONCLUSIONS-Adiponectin is a powerful marker of diabetes risk in subjects at high risk for diabetes, even after adjustment for weight. An increase in adiponectin in the lifestyle and placebo groups was associated with a reduction in diabetes risk. However, these changes in adiponectin were comparatively small and less strongly related to diabetes outcome than baseline adiponectin levels.

AB - OBJECTIVE-To determine whether baseline adiponectin levels or intervention-associated change in adiponectin levels were independently associated with progression to diabetes in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS-Cox proportional hazards analysis was used to evaluate the contribution of adiponectin and treatment-related change in adiponectin to risk of progression to diabetes. RESULTS-Baseline adiponectin was a strong independent predictor of incident diabetes in all treatment groups (hazard ratio per ∼3 μg/ml higher level; 0.61 in the lifestyle, 0.76 in the metformin, and the 0.79 in placebo groups; all P < 0.001, P = 0.13 comparing groups). Baseline differences in adiponectin between sexes and race/ethnicity groups were not reflected in differences in diabetes risk. DPP interventions increased adiponectin levels ([means ± SE] 0.83 ± 0.05 μg/ml in the lifestyle group, 0.23 ± 0.05 μg/ml in the metformin group, and 0.10 ± 0.05 μg/ml in the placebo group; P < 0.001 for increases versus baseline, P < 0.01 comparing groups). These increases were associated with reductions in diabetes incidence independent of baseline adiponectin levels in the lifestyle and placebo groups but not in the met-formin subjects (hazard ratio 0.72 in the lifestyle group (P < 0.001), 0.92 in the metformin group (P = 0.18), and 0.89 in the placebo group; P = 0.02 per ∼1 μg/ml increase, P = 0.02 comparing groups). In the lifestyle group, adjusting for change in weight reduced, but did not remove, the effect of increased adiponectin. CONCLUSIONS-Adiponectin is a powerful marker of diabetes risk in subjects at high risk for diabetes, even after adjustment for weight. An increase in adiponectin in the lifestyle and placebo groups was associated with a reduction in diabetes risk. However, these changes in adiponectin were comparatively small and less strongly related to diabetes outcome than baseline adiponectin levels.

UR - http://www.scopus.com/inward/record.url?scp=42449162285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449162285&partnerID=8YFLogxK

U2 - 10.2337/db07-1419

DO - 10.2337/db07-1419

M3 - Article

C2 - 18192541

AN - SCOPUS:42449162285

VL - 57

SP - 980

EP - 986

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 4

ER -